San Diego-based mostly Viking Therapeutics marked itself as a significant competitor from the weight loss drug sector in February right after revealing promising data from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in March the